We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
5.00 | 0.29% | 1,733.50 | 1,732.50 | 1,733.00 | 1,739.50 | 1,724.50 | 1,733.00 | 4,237,056 | 16:35:18 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.48 | 71.35B |
Date | Subject | Author | Discuss |
---|---|---|---|
21/6/2018 15:03 | Yes, and reflecting drop in whole FTSE | tradermichael | |
21/6/2018 14:58 | supermarky - it might be a reaction to sterling spiking up a cent at noon, presumably a reaction to the MPC announcement. See | zho | |
21/6/2018 14:47 | Whats with the drop at 12 noon? | supermarky | |
21/6/2018 11:43 | That’s possible good news for later in the year, dont GSK earnings get a boost from lower £, considering most of their earnings are outside the Uk? 1540/50p support level. Bought another chunk @ 1533p | ny boy | |
20/6/2018 16:56 | GSK takes billion-dollar drug fight with Gilead to top AIDS meeting | philanderer | |
20/6/2018 09:55 | x-posted from the IMB board... 'FWIW from Motley Fool, that said there is more fact-based content to this article than the usual blind puffery. It's a concise summary of how things stand today with some metrics, together with a look ahead. 'My 3 favourite FTSE 100 5% yielders'. dd: today The three are IMB, GSK, and ITV.' | jrphoenixw2 | |
19/6/2018 15:45 | This is a pretty good performance over 2 days during which the market has been under pressure, especially yesterday - I did offload some at 1580+, but thought it might go lower than it has, 1535 intraday. So have not added them back (put it elsewhere), but still hold a good chunk. Looks like it will end up for the day and that is an excellent result having tested 1540, the previous resistance, twice in the two days. | imastu pidgitaswell | |
19/6/2018 12:41 | I bought a substantial quantity this morning ….. ;0) | tradermichael | |
19/6/2018 10:42 | Some are buying the dips, defensive qualities kicking in? | ny boy | |
18/6/2018 15:02 | DF Nigeria!!! | toffeeman | |
18/6/2018 14:13 | It should be remembered that the UK part of Horlicks was sold last year. The current mooted sale relates to a majority holding in the Indian-based business which is much larger. The brand still holds a significant position in the nutritional food market, there where apparently Horlicks is a very popular breakfast drink for numerous school children. However, Horlicks cannot be regarded as a core activity within the consumer healthcare side of the business. Furthermore, any funds raised were not earmarked for the dividend and reorganisation but would, as announced in March, be applied to the buyout of the remaining $13 billion stake in its much larger consumer healthcare joint venture with Novartis. | grahamburn | |
18/6/2018 14:12 | Yes I have broadly dismissed the Horlicks deal, maybe a small boost when it happens but just adding on defensive qualities and improving news flow. Should continue the rally, as long as 1540/1550p holds as support, next target over the medium term is 1690p | ny boy | |
18/6/2018 12:52 | I don't see a Horlicks deal as particularly positive. A sale to raise money to fund costs (reorganisation and dividend) plus it appears muddled thinking on the non Pharma business. | alphorn | |
18/6/2018 09:12 | Added another 1000 @ 1545p | ny boy | |
17/6/2018 06:35 | GSK Chief-Exec Emma Walmsley: '...its sale would help meet its priorities of overhauling its pharmaceutical division and maintaining a dividend.' | jrphoenixw2 | |
17/6/2018 00:21 | Coca-Cola and Heinz in £3bn battle for Horlicks US drinks giant Coca-Cola is mulling a £3bn swoop for Horlicks after GlaxoSmithKline (GSK) hoisted a “for sale” sign above the 145-year-old brand. The Sunday Telegraph understands the soft drinks juggernaut is among a clutch of potential bidders, including Kraft Heinz and Nestle, which have held early talks over a deal for the malted milk drink. Morgan Stanley, the US investment bank, is advising GSK on the sale, according to sources. | philanderer | |
15/6/2018 15:26 | Why is this not £18 already to be frank. Is the Standard still considered a newspaper? | romeike | |
15/6/2018 13:29 | Glaxo faces lawsuit as salesman claims he was bullied for whistleblowing | philanderer | |
15/6/2018 08:49 | Sold some, kept more - hard to leave all of 25%+ just sitting there. Quickish run up and suspect at some point we will see low 1500s again, at least intra-day. But no great insight, just a hunch. | imastu pidgitaswell | |
14/6/2018 14:03 | I was hoping for a high of 15.50 today. I am delighted with the current price of 15.70. I visited the Montrose GSK site yesterday and told my wife I was very impressed. She told her friends so maybe this accounts for the leap in SP!!! | jadeticl3 | |
14/6/2018 13:03 | Nice test of 1550p this morning, is acting as support | ny boy | |
14/6/2018 09:27 | Liberum reiterating 'buy' | philanderer | |
14/6/2018 09:08 | Broken through 1550p resistance, any pull back and I will add more, still an attractive annual divi, paid quarterly, decent news flow coming through is supportive. | ny boy | |
14/6/2018 08:42 | And a well timed release to get over the 1540-50 barrier. No doubt plenty of retesting to come... | imastu pidgitaswell | |
14/6/2018 08:13 | That's another two pieces of very positive news this week …..;0) | tradermichael |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions